IMPROVE-IT (TIMI 40) determined whether the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, improves cardiovascular outcomes compared with simvastatin monotherapy in patients after ACS. In addition, the difference in achieved LDL-C levels between the groups provided data on whether the target for LDL-C lowering should be reduced further.
MAIN RESULTS:
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
N Engl J Med. 2015 Jun 18;372(25):2387-97.
PRESENTATIONS
Biomarkers (Qamar, AHA 2017) Association of Genetic Risk Score with Risk of Recurrent Coronary Events in IMPROVE-IT (Ruff, AHA 2018)
Ezetimibe Consistently Reduces LDL-C with Little Interindividual Variability in 14,970 Patients Post-ACS (Patel, AHA 2021)
Ezetimibe Consistently Reduces LDL-C with Little Interindividual Variability in 14,970 Patients Post-ACS (Patel, AHA 2021)
OTHER PUBLICATIONS
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov;156(5):826-32.An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May;159(5):705-9.